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Background: Patients with trophoblastic diseases pro-
duce ordinary and irregular forms of human chorionic
gonadotropin (hCG; e.g., nicked hCG, hCG missing the
b-subunit C-terminal segment, hyperglycosylated hCG,
and free b subunit) that are recognized to differing
extents by automated immunometric hCG (or hCGb)
assays. This has led to low or false-negative results and
misdiagnosis of persistent disease. False-positive hCG
immunoreactivity has also been detected, leading to
needless therapy for trophoblastic diseases. Here we
compare seven commonly used hCG assays.
Methods: Standards for five irregular forms hCG pro-
duced in trophoblastic diseases, serum samples from 59
patients with confirmed trophoblastic diseases, and
serum samples from 12 women with previous false-
positive hCG results (primarily in the Abbott AxSYM
assay) were blindly tested by commercial laboratories in
the Beckman Access hCGb, the Abbott AxSYM hCGb,
the Chiron ACS:180 hCGb, the Baxter Stratus hCG test,
the DPC Immulite hCG test, the Serono MAIAclone
hCGb tests, and in the hCGb RIA.
Results: Only the RIA and the DPC appropriately
detected the five irregular hCG standards. Only the
Beckman, DPC, and Abbott assays gave results similar
to the RIA in the patients with confirmed trophoblastic
diseases (values within 25% of RIA in 49, 49, and 54 of
59 patients, respectively). For samples that were previ-
ously found to produce false-positive hCG results, no
false-positive results were detected with the DPC and
Chiron tests (5 samples, median <2 IU/L), but up to
one-third of samples were false positive (>10 IU/L) in
the Beckman (1 of 5), Serono (2 of 9), and Baxter assays
(1 of 5), and the hCGb RIA (3 of 9; median for all assays,
<5 IU/L). These samples, which produced false-positive
results earlier in the Abbott AxSYM assay, continued to
produce high values upon reassessment (median, 81
IU/L).
Conclusions: Of six frequently used hCG immunomet-
ric assays, only the DPC detected the five irregular
forms of bhCG, agreed with the RIA, and avoided
false-positive results in the samples tested. This assay,
and similarly designed assays not tested here, seem
appropriate for hCG testing in the diagnosis and man-
agement of trophoblastic diseases.
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Human chorionic gonadotropin (hCG) is composed of
two peptides, the a and b subunits, joined noncovalently.
Approximately 30% of the molecular weight of hCG
comprises carbohydrate side chains: four N-linked oligo-
saccharide and four O-linked oligosaccharides. The hCG
a and b subunits are heterogeneous in both peptide and
oligosaccharide side chain structures (1, 2). Ordinary hCG
(a-b dimer with no cleavages, monoantennary or bianten-
nary N-linked oligosaccharides, and trisaccharide and
tetrasaccharide O-linked oligosaccharides) is the principal
form of hCG in serum during normal pregnancy. Ordi-
nary hCG is accompanied by small and varying amounts
of nicked hCG (cleaved on the b subunit, between resi-
dues 47 and 48), hyperglycosylated hCG (hCG with an
abundance of larger or triantennary N-linked oligosaccha-
rides and hexasaccharide O-linked oligosaccharides),
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nicked and hyperglycosylated hCG, free b subunit, nicked
free b subunit, free a subunit, and large free a subunit (a
subunit with triantennary N-linked oligosaccharides)
(1, 2). Commercial hCG (or hCGb) assays all detect ordi-
nary hCG, and to various extents detect nicked hCG,
hyperglycosylated hCG, nicked and hyperglycosylated
hCG, and nicked and nonnicked free b subunit. None of
the commercial hCG (or hCGb) methods detect either
form of free a subunit (2 ). With the preponderance of
ordinary hCG in normal pregnancy serum, the ability of
the assay to fully detect nicked hCG, hyperglycosylated
hCG, nicked and hyperglycosylated hCG, and nicked and
nonnicked free b subunit may make only a small differ-
ence to the immunoassay results and to the utility of the
assay for pregnancy testing (1, 3, 4).
Trophoblastic diseases include complete and partial
hydatidiform mole, postmolar tumor, gestational chorio-
carcinoma, testicular choriocarcinoma, and placental site
trophoblastic disease. These are also major sources of
hCG. Precise hCG determinations are crucial in patients
with trophoblastic diseases to assess the mass of tumor,
the successful treatment of malignancy, or recurrence or
persistence of disease (3–5). In trophoblastic diseases,
hyperglycosylated hCG, nicked hCG, hyperglycosylated
and nicked hCG, or nicked or nonnicked free b subunit
may be the principal source of immunoreactivity in serum
(2–7). Additional hCG variants are found in patients with
trophoblastic diseases. These include nicked hCG missing
the b subunit C-terminal peptide, residues 92–145, and
alternatively nicked hCG (cleaved at b43–44 or b44–45)
(1 ). The inability of commercial hCG tests to fully detect
these hCG variants has led to failure to detect persistent or
recurrent trophoblastic diseases, requiring urgent chemo-
therapy or other surgery (4, 8, 9).
Several centers have claimed that the competitive poly-
clonal anti-hCGb RIA is the only type of assay that detects
all of these variants equally and is the only test appropri-
ate for monitoring trophoblastic diseases (4, 7, 10, 11). For
this reason, the hCGb RIA has been proclaimed the “gold
standard” for hCG testing in trophoblastic disease appli-
cations (4, 7). A hCGb RIA should not be mistaken for a
hCG, hCGa, or hCGb C-terminal peptide RIA, which may
be much less broad in specificity. Other laboratories have
found that newer immunometric assays and automated
immunometric assays may also be appropriate for tropho-
blastic disease management or may even offer an im-
provement for this application (6, 12–15). Our objective
was to thoroughly examine the appropriateness of differ-
ent hCG (or hCGb) assays for monitoring patients with
trophoblastic diseases. We examined the ability of six of
the most commonly used automated immunometric as-
says to detect hCG and its variants in trophoblastic
disease cases and to avoid unduly low or false-negative
immunoassay values. Results were compared with a
commercial laboratory’s competitive hCGb RIA, the gold
standard.
A recent article identified 12 patients falsely treated for
presumed choriocarcinoma because of false-positive hCG
results (16, 17). Other reports have also identified patients
erroneously diagnosed with choriocarcinoma because of
false-positive hCG results (9, 18, 19). False-positive hCG
results have also been identified in three patients after
evacuation of complete hydatidiform mole (Cole LA and
Butler SA, unpublished data). This can lead to false
diagnosis of a postmolar tumor. A recent report from the
Trophoblastic Disease Center in London noted that a
significant proportion of choriocarcinoma cases are pre-
sumed solely on the basis of persistently increased hCG
results (20 ). Most cases of postmolar tumor are assumed
on the basis of increased hCG results after evacuation of a
complete hydatidiform mole. Our objective was to also
examine the accuracy of hCG (or hCGb) assays for diag-
nosing patients with choriocarcinoma or postmolar tu-
mor. Samples that had been found to produce false-
positive results previously (16, 17, 19) were examined
using the same six automated immunometric hCG (or
hCGb) tests and the hCGb RIA.
Materials and Methods
Serum samples were collected at Charing Cross Hospital,
London, from 50 women, and from other centers through-
out the world from an additional 9 women with con-
firmed trophoblastic diseases. Of the 59 women, 8 had
pathology-confirmed choriocarcinoma, and 51 had com-
plete hydatidiform mole. Of the latter, 30 provided serum
samples for this study preevacuation of the mole or in the
2 weeks following evacuation (hCG .500 IU/L), and 21
provided a sample in the later weeks following evacua-
tion of the mole (2–6 weeks; hCG ,500 IU/L) when the
hCG concentration was slowly decreasing.
In addition to these 59 serum samples, five standards
were prepared from pure hCG preparations. These were
pure hyperglycosylated hCG, pure nicked hCG, pure
asialo hCG (hCG missing sialic acid residues on N- and
O-linked oligosaccharides), pure hCG minus the C-termi-
nal peptide, and nonnicked free b subunit. These were
purified and prepared from pregnancy, complete hyda-
tidiform mole, or choriocarcinoma urine samples, as de-
scribed previously (1 ). Peptide and oligosaccharide struc-
tures had been determined to fully characterize the
preparations (1 ).
Additional serum samples were collected from 12
women erroneously diagnosed as having choriocarci-
noma or gestational trophoblastic disease because of
false-positive hCG results (16, 17). In all 12 cases, the
false-positive results were seemingly attributable to the
presence of heterophilic antibodies in blood (Cole LA and
Shahabi S, unpublished data). All 12 women were shown
to lack measurable concentrations (.2 IU/L) of true hCG
or its breakdown products (16, 17). The 12 serum samples
were those sequentially accrued by the hCG Reference
Service and were not selected in any way. Ten of the 12
patients were falsely monitored by their physicians, using
the Abbott AxSYM hCGb test, 1 patient was monitored
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using both the Abbott AxSYM and IMx hCGb tests, and 1
was monitored using the Bayer Immuno-1 hCGb assay.
On the basis of the hCG results supplied by Charing
Cross Hospital and patient treatment centers, the 59
confirmed trophoblastic disease serum samples were each
diluted with normal male serum (Sigma) to ;200 IU/L
(samples with hCG ,200 IU/L were not diluted). The five
hCG structure standards were calibrated by amino acid
analysis. Results were converted to IU/L hCG, or molar
equivalents of hCG based on the molecular weights of
hCG and its b subunit (21 ), using the formula established
by the World Health Organization for the preparation of
the First International Reference Preparation and the
Third International Standard for immunoassays (1 mg of
pure hCG 5 9.3 IU) (22 ). Standards were diluted in
normal male serum to a concentration of 200 IU/L or the
molar equivalent (0.57 pmol/L hCG).
The trophoblastic disease patient samples, the 5 stan-
dards, and 4 of the 12 false-positive serum samples (only
4 samples were available at the time of initial coding), a
total of 68 samples, were mixed, coded, and sent to
independent commercial laboratories for blind testing.
The remaining eight false-positive samples were tested by
commercial laboratories at later times, when samples
became available.
Samples were tested by four commercial laboratories.
The Chemistry Laboratory in the Department of Pathol-
ogy at Hurley Medical Center (Flint, MI) blindly tested
coded samples in the Beckman Access hCGb (total hCG),
the Abbott AxSYM hCGb (total hCG), the Chiron ACS:180
hCGb (total hCG), and the Baxter Stratus hCG test (intact
hCG). This was carried out by Dr. Harland Verrill as part
of a collaboration, without charge. Two of the samples
were tested by the Abbott AxSYM hCGb assay at Quest
Diagnostics (Teterboro, NJ). The Endocrinology Labora-
tory at Yale-New Haven Hospital (New Haven, CT)
blindly tested the coded samples in the Serono
MAIAclone hCGb (total hCG) and in their tumor marker
hCG test, a goat polyclonal anti-hCGb competitive RIA
(total hCG test; 3-day assay using rabbit polyclonal anti-b
antisera and 125I-hCG tracer, bound material precipitated
with goat anti-rabbit g-globulin). A standard immunoas-
say fee was paid for this service. Finally, the DPC Immu-
lite hCG test (total hCG) was run blindly at the laborato-
ries of Diagnostic Products Corp. (Los Angeles, CA)
without charge. This is an independent research study.
The authors received no funds from, and have neither
personal interest in nor conscious bias for or against any
of the described manufacturers.
Results were decoded and entered into a Microsoft
Excel spreadsheet. The six automated immunometric as-
say hCG/hCGb assay values were compared with the
hCGb RIA results, and we tabulated the number of
samples in which results were .25% below or .25%
above the RIA result. Because individual hCG values
usually are logarithmically distributed (23, 24), the me-
dian results are presented.
Results
Seventy-six serum samples (5 hCG variant standards, 8
samples from patients with choriocarcinoma, 51 from
those with complete hydatidiform mole, and 12 from
those with confirmed false-positive hCG results) were
tested by independent laboratories in six automated im-
munometric hCG/hCGb assays and by an hCGb RIA.
The six examined assays varied in their recognition of
purified (200 IU/L) hCG variants (Table 1). The Serono
MAIAclone hCGb assay ineffectively recognized free b
subunit (3.8% recovery), hyperglycosylated hCG (3.9%),
and nicked hCG (27%). The Baxter Stratus hCG test did
not detect free b-subunit standard (,1% recovery). The
Chiron ACS:180 hCGb test underdetected free b-subunit
standard (70%). Three tests, the Beckman Access, Abbott
AxSYM, and Chiron ACS:180, did not detect the hCG
minus C-terminal peptide (,1% recovery). The commer-
cial hCGb RIA (the gold standard) and the DPC Immulite
hCG automated immunometric assay were the only tests
with apparent recoveries of at least 75% for all five
hCG-related molecule standards.
We examined the detection of hCG and related mole-
cules in serum samples from patients with complete
hydatidiform mole. Samples from 30 patients were col-
lected before and up to 2 week after evacuation of a
complete hydatidiform mole (Table 2). Additional sam-
Table 1. Ability of hCG immunoassays to measure hCG metabolic productsa commonly found in individuals with
trophoblastic disease or choriocarcinoma.
Standardd
(molar equivalent of 200 IU/L)
Commercial
hCGb RIA,
IU/L
Beckman
Access hCGb,
IU/L
Abbott AxSYM
hCGb, IU/L
Chiron ACS:180
hCGb, IU/L
DPC Immulite
hCG, IU/L
Baxter
Stratus hCG,
IU/L
Serono
MAIAclone,
IU/L
Free b-subunit 171 356 200 140 234 <2 7.6
Hyperglycosylated hCG 184 255 181 234 207 189 7.8
Nicked hCG (cleaved b47–48) 195 224 242 194 235 169 54
Asialo hCG 248 175 243 162 285 191 185
hCG minus C-terminal peptide 190 <2 <2 <2 273 190 147
Number of low results (,150 IU/L) 0 of 5 1 of 5 1 of 5 2 of 5 0 of 5 1 of 5 4 of 5
a The precise structures of these preparations have been published (1). All standards were calibrated by amino acid analysis and converted into the international
units, based on molecular weight and molar equivalents of hCG. Samples were coded and tested blindly by multiple external laboratories as described in Materials and
Methods. Unduly low (,150 IU/L of 25% below calibrated concentration) results are in bold.
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ples were collected from 21 patients at 2–6 weeks after
evacuation of hydatidiform mole (Table 3), and from 8
women with choriocarcinoma (Table 4). Results from the
six automated immunometric assays were compared with
those from the commercial laboratory’s hCGb RIA. For
the purposes of this study, errors were considered as
results deviating from the RIA value by .25%. The fewest
errors were found with the Abbott AxSYM hCGb test
(5 errors in 59 patients total; 8.5%) and with the DPC
Immulite hCG and Beckman Access hCG (10 errors
total; 17%). More errors were found with the Serono
MAIAclone (14 errors total; 24%) and with the Chiron
ACS:180 hCGb (16 errors total; 27%). The most errors
were noted with the Baxter Stratus hCG (22 errors total;
37%).
Most of the errors were noted in samples taken 2–6
weeks after evacuation of hydatidiform mole (Table 3)
and with choriocarcinoma serum samples (Table 4). These
errors were particularly evident with the Chiron ACS:180
hCGb test (errors in 5 of 21 mole and 5 of 8 choriocarci-
noma cases), the Serono MAIAclone assay (errors in 7 of
21 mole and 6 of 8 choriocarcinoma cases), and the Baxter
Stratus hCG assay (errors in 15 of 21 mole and 5 of 8
choriocarcinoma cases).
We also examined serum from 12 patients with a
history of false-positive hCG results (Table 5). These were
tested in the commercial RIA and in the six automated
immunometric assays. Insufficient serum was available to
test all samples in each of the seven assays. We considered
false-positive results .10 IU/L for diagnosis of tropho-
blastic disease (or pregnancy). Concentrations up to 10
IU/L hCG can be produced by the pituitary and other
Table 2. Analysis of serum from 30 patients before and up to 2 weeks after evacuation of a complete hydatidiform mole
(hCG >500 IU/L total).a
Total hCG
concentration,b
IU/L
Dilution supplied
to test centers
Commercial
hCGb RIA,
IU/L
Beckman
Access hCGb,
IU/L
Abbott AxSYM
hCGb, IU/L
Chiron ACS:180
hCGb, IU/L
DPC Immulite
hCG, IU/L
Baxter
Stratus hCG,
IU/L
Serono
MAIAclone,
IU/L
560 5 112 123 121 121 112 91 112
740 10 74 84 81 86 73 69 80
760 10 76 97 111 90 83 66 75
780 10 78 92 72 100 77 76 86
800 10 80 93 70 94 75 67 80
1020 5 204 220 197 223 206 179 220
1210 10 121 137 134 147 110 108 121
1420 10 142 162 157 150 130 100 128
1800 10 180 209 184 218 174 159 187
2700 30 90 112 101 115 86 76 85
3630 30 121 128 124 137 108 105 122
3930 30 131 142 146 154 125 102 122
4250 10 425 284 353 245 219 130 171
4560 60 76 99 83 100 83 82 91
5340 30 178 176 164 191 149 150 175
5640 60 94 110 98 115 90 93 105
6120 60 102 107 114 111 96 90 103
6810 30 227 245 236 245 214 181 222
6900 60 115 137 119 152 108 105 123
8100 30 270 279 245 283 241 237 264
8250 150 55 51 45 59 59 48 53
10 560 60 176 203 165 214 167 164 179
12 750 150 85 106 88 142 94 88 99
14 700 150 98 132 110 162 110 105 122
16 200 150 108 139 114 178 119 110 121
23 850 150 159 174 154 213 140 133 144
25 000 1000 25 41 36 50 35 33 35
27 150 150 181 262 239 284 220 201 225
44 000 400 110 129 115 162 107 103 121
54 400 400 136 174 163 209 143 146 168
Median result 114 134 120 151 110 104 122
Total number varying .25% from RIA result 2 of 30 0 of 30 6 of 30 1 of 30 2 of 30 1 of 30
a Samples were tested for hCG in a RIA, and results were compared with those for 6 immunometric assays. Samples were diluted to 200 IU/L based on the Charing
Cross house immunoassay, coded, and tested blindly by multiple external laboratories as described in Materials and Methods. Results varying .25% from commercial
hCGb RIA values are indicated in bold.
b As determined from dilution and commercial hCGb RIA.
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sources (3, 10, 12). None of the samples tested exceeded
10 IU/L in the DPC Immulite hCG or the Chiron ACS:180
hCGb test (0 of 6 and 0 of 5 samples, respectively). Less
than one-third of the samples tested exceeded 10 IU/L in
the Baxter Status hCG, Beckman Access hCGb, and Se-
rono MAIAclone hCGb assays, or in the commercial
hCGb RIA (1 of 5, 1 of 5, 2 of 9, and 3 of 9 samples,
respectively). Because most of these samples were known
to produce false-positive results in the Abbott AxSYM
assay, we expected and found false-positive results in the
Abbott AxSYM hCGb test (10 of 10 samples).
To evaluate the extent of false positivity, we calculated
Table 3. Analysis of serum from 21 patients with low hCG 2–6 weeks (<500 IU/L total) after evacuation of complete
hydatidiform mole.a
Total hCG
concentration,b
IU/L
Dilution supplied
to test centers
Commercial
hCGb RIA,
IU/L
Beckman
Access
hCGb, IU/L
Abbott AxSYM
hCGb, IU/L
Chiron ACS:180
hCGb, IU/L
DPC
Immulite hCG,
IU/L
Baxter
Stratus hCG,
IU/L
Serono
MAIAclone,
IU/L
5.0 1 5.0 8.7 7.1 4.6 5.9 3.2 5.3
10 1 10 11 10 7.1 9.2 8.8 12
12 1 4 5.8 5.1 3.3 4 <2 12
12 1 12 15 16 14 13 12 16
13 1 13 18 18 14 11 5.7 8.5
14 1 14 10 10 6.6 8.8 6.9 8.1
17 1 17 16 16 11 11 7.1 14
26 1 26 25 26 22 19 15 24
30 1 30 36 40 30 29 15 24
59 1 59 65 70 67 115 91 79
60 2 30 36 43 32 24 17 22
62 2 31 45 46 44 35 28 33
94 2 47 61 76 52 55 34 41
124 2 62 45 44 41 41 30 31
132 2 66 88 99 80 73 53 66
162 1 162 31 48 15 235 <2 12
175 5 35 47 46 51 41 43 53
216 2 108 107 123 94 103 69 86
236 2 118 128 146 130 112 86 106
246 2 123 121 111 113 92 32 50
400 5 80 85 93 70 75 60 75
Median result 31 36 44 32 35 28 24
Total number varying .25% from RIA result 4 of 21 4 of 21 5 of 21 6 of 21 15 of 21 7 of 21
a Samples were tested for hCG in a RIA, and results were compared with those for 6 immunometric assays. Samples were diluted to 200 IU/L based on the Charing
Cross house immunoassay, coded, and tested blindly by multiple external laboratories as described in Materials and Methods. Assay results that were reported as
0, ,1, or ,2 IU/L are marked as ,2 IU/L. Results varying ,25% from commercial hCGb RIA values are indicated in bold.
b As determined from dilution and commercial hCGb RIA.
Table 4. Analysis of serum samples from 8 patients with choriocarcinoma by an hCGb RIA and comparison with results
from 6 hCG immunometric assays.a
Total hCG
concentration,b
IU/L
Dilution
supplied to
test centers
Commercial
hCGb RIA,
IU/L
Beckman
Access hCGb,
IU/L
Abbott AxSYM
hCGb, IU/L
Chiron ACS:180
hCGb, IU/L
DPC Immulite
hCG, IU/L
Baxter Stratus
hCG, IU/L
Serono
MAIAclone,
IU/L
75 1 75 107 98 109 85 82 235
99 1 99 128 126 102 101 78 96
120 1 120 244 115 87 182 19 9
580 10 58 84 60 96 55 69 61
11 940 30 398 213 319 248 544 267 253
131 000 1000 131 170 121 130 126 67 75
229 000 1000 229 122 185 68 200 81 89
3 456 000 16000 216 11 14 6.9 55 109 19
Median result 126 125 118 99 114 79 82
Total number varying .25% from RIA result 4 of 8 1 of 8 5 of 8 3 of 8 5 of 8 6 of 8
a Samples were diluted to 200 IU/L based on the Charing Cross house immunoassay, coded, and tested blindly by multiple external laboratories as described in
Materials and Methods. Results varying .25% from commercial hCGb RIA values are indicated in bold.
b As determined from dilution and commercial hCGb RIA.
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the median concentrations. The median result was ,2
IU/L in four of the assays and ,5 IU/L in two other
assays. In the Abbott AxSYM hCGb test, however, the
median was 81 IU/L.
Discussion
All quantitative serum hCG assays sold in the United
States have a warning in their package insert noting that
they are approved by the Food and Drug Administration
(FDA) only for, and have been tested only for, normal
pregnancy testing applications. Today, however, a high
proportion of hCG tests run by all clinical laboratories are
for non-FDA-approved or other applications. These in-
clude second-trimester Down syndrome screening, detec-
tion of ectopic pregnancies, management of hyperemesis
gravidarum, diagnosis and management of trophoblastic
diseases, and diagnosis and management of testicular and
germ cell neoplasms. More than 50 different quantitative
serum hCG tests are used today in clinical laboratories
throughout the United States. All are used, without hes-
itation or question about hCG specificity, for anything
from pregnancy detection to monitoring chemotherapy
for choriocarcinoma (2, 4, 5, 10, 25).
Textbooks on obstetrics and gynecology emphasize the
essentiality of hCG testing in patients with trophoblastic
diseases. This is a mandated application, although it is not
approved by the FDA and has not been formally tested by
hCG assay manufacturers. hCG is the vital test in the
identification of choriocarcinoma, differentiating this can-
cer from others. It acts as a perfect tumor marker (100%
sensitivity) for managing the treatment for choriocarci-
noma and for detecting recurrences of disease (18, 25).
Although hCG testing is not essential in the diagnosis of
hydatidiform mole, it is essential for demonstrating the
complete removal of molar tissue and for the rapid
identification of postmolar tumor or persistent tropho-
blastic disease (26 ). Problems have been reported in the
use of hCG immunoassays for both detecting (false-
positive results) and monitoring the progress of (false-
negative or unduly low results) trophoblastic diseases
(2–8, 10). In this study, we examined the performance of
the competitive hCGb RIA (the gold standard hCG test
for trophoblastic diseases) and six of the most commonly
used automated immunometric assays in diagnosing and
monitoring hydatidiform mole and choriocarcinoma.
Hyperglycosylated hCG, nicked hCG, hCG minus C-
terminal peptide, asialo hCG, and free b subunit are either
unique to trophoblastic diseases or more abundant in
trophoblastic disease samples (1, 2–7). Only the hCGb
RIA and the DPC test effectively detected all of the hCG
breakdown products or glycosylation variants. Not sur-
prisingly, three tests, the Beckman, Abbott, and Chiron
assays, did not detect hCG minus C-terminal peptide. The
C-terminal peptide is a commonly used hCG epitope
because it is unique to the b subunit of hCG and is not
present on luteinizing hormone. Other b-subunit core
epitopes can be targeted to effectively differentiate hCG
and luteinizing hormone (2 ).
Considering the assay specificities, we examined se-
rum from 59 patients with confirmed trophoblastic dis-
eases. Results were compared with the hCGb RIA. Three
tests (the Abbott, the DPC, and the Beckman) performed
well, with few important differences in results compared
with the hCGb RIA. For three of the six tests (the Serono,
Chiron, and Baxter tests), however, 24%, 27%, and 37% of
results compared poorly with the hCGb RIA. Errors were
Table 5. Analysis of serum samples from 12 patients erroneously diagnosed with choriocarcinoma or gestational
trophoblastic disease based on false-positive hCG data (16).a
Commercial
hCGb RIA,
IU/L
Beckman
Access hCGb,
IU/L
Abbott AxSYM
hCGb, IU/L
Chiron ACS:180
hCGb, IU/L
DPC Immulite
hCG, IU/L
Baxter
Stratus hCG,
IU/L
Serono
MAIAclone,
IU/L
NDb ND ND ND ND 53 ND
ND ND 150 ND ND ND ND
ND ND ND ND ,2 ND ND
,2 ND 17 ND ND ND ,2
28 30 14 9.7 ND ,2 ,2
,2 ,2 32 ,2 ,2 ,2 133
,2 ND 33 ND ,2 ND ,2
,2 4.6 68 ,2 ,2 ,2 2.0
,2 ND 93 ND ND ND 3.5
10 6.6 110 4.5 4.19 2.6 13
11 ND 145 ND ND ND 3.5
11 ,2 175 ,2 ,2 ND 7.8
Median reported concentration ,2 4.6 81 ,2 ,2 ,2 3.5
.10 IU/L reported 3 of 9 1 of 5 10 of 10 0 of 5 0 of 6 1 of 5 2 of 9
a Samples were tested for hCG by the hCGb RIA and 6 immunometric assays. Samples were coded and tested blindly by multiple external laboratories as described
in Materials and Methods. Assay results reported by testing centers as 0, ,1, or ,2 IU/L were considered at the limit of detection and were recorded as ,2 IU/L.
False-positive values exceeding 10 IU/L are indicated in bold. All samples were supplied to test centers undiluted.
b ND, not determined. Insufficient serum available to run test.
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most evident with these three assays in serum samples
from women 2–6 weeks after evacuation of hydatidiform
mole and in samples from patients being monitored for
choriocarcinoma (34%, 45%, and 69% errors, respectively).
These are clinical situations in which accurate hCG mea-
surements are needed. We infer that theses three assays,
and other similar assays not tested in this study, should
probably be avoided in the management of trophoblastic
disease. These three assays (Serono, Chiron, and Baxter)
have minimal or less than normal detection of free b
subunit. This is the likely cause of the poor performance
in samples from patients with trophoblastic diseases.
Clearly, equimolar detection of hCG and free b subunit is
important in the management of trophoblastic diseases
(2–7). The Serono test also poorly detected nicked hCG
and hyperglycosylated hCG, which are also important in
the management of trophoblastic diseases (1, 2, 4).
In four individual cases (patients with total hCG con-
centrations of 14, 124, 162, and 3 456 000 IU/L; see Tables
3 and 4), unduly low results were found with three other
assays (Beckman, Abbott, and Chiron). These three meth-
ods did not detect hCG minus C-terminal peptide. Detec-
tion of this hCG degradation product may also be impor-
tant in the management of patients with trophoblastic
diseases.
Patients can be diagnosed with choriocarcinoma solely
from a persistent positive hCG result, in the absence of an
imaged tumor or a pregnancy (16, 18). In most cases,
chemotherapy or surgery is initiated solely because of
persistent positive hCG results (16 ). False-positive hCG
results can occur in the hCG assay, and patients have been
erroneously diagnosed and treated for choriocarcinoma.
The hCG Reference Service has now identified 20 such
false choriocarcinoma cases; 14 needlessly received sur-
gery or chemotherapy [Ref. (16 ) and Cole LA, unpub-
lished data]. False-positive results have also been ob-
served in three patients after evacuation of hydatidiform
mole (Cole LA and Butler SA, unpublished data). False-
positive hCG results typically come from heterophilic
antibodies present in human serum (9, 16, 18, 27). We
used such sera from the initial 12 patients identified with
false-positive hCG results at the hCG Reference Service
(16, 17) to further evaluate the hCGb RIA and the six
automated immunometric tests.
The DPC and Chiron assays produced no false-positive
results (,10 IU/L). Up to one-third of samples gave
false-positive results with the hCGb RIA, and the Beck-
man, Baxter, and Serono assays. It is important to note
that 11 of the 12 sera were from patients who had been
tested earlier using the Abbott AxSYM test. In fact, 19 of
the 20 patients identified to date by the hCG Reference
Service with false-positive hCG had been monitored by
their physicians using the Abbott AxSYM test [Ref. (16 )
and Cole LA, unpublished data]. It is no surprise that 10
of 10 samples evaluated here were falsely positive in this
assay. The median false-positive hCG result was 81 IU/L
in the Abbott test, and ,5 IU/L in all other tests. Such
(lower) false-positive results found in the other assays are
less likely to meet the threshold for the assumed diagnosis
of choriocarcinoma and for therapy (16 ). The finding of
multiple serum samples positive in the Abbott test and
serum samples producing lower or negative results in
other assays suggests a potential problem with this test.
We have examined the specificity of hCG immunoas-
says for detecting variant forms of hCG present in tropho-
blastic diseases, compared the utility of automated hCG
immunometric assays with the hCGb RIA in the manage-
ment of trophoblastic diseases, and have examined the
potential of hCG assays to give false-positive results. Only
the DPC gave consistently acceptable results in all three
categories. The DPC test is a chemiluminescence test,
using a capture antibody and a tracer antibody directed
toward different regions of the core of hCG b subunit.
Several other commercial tests use similar antibody ar-
rangements (2 ). These assays might be similarly utilized
in the management of trophoblastic diseases. The DPC
and similarly designed tests may be as useful as hCGb
RIA in the management of trophoblastic diseases. One
must consider the negative aspects of an hCGb RIA,
including its complexity, the extensive pipetting, its rela-
tive imprecision, and its time-consuming procedures.
The DPC test and the hCGb RIA both appropriately
recognized all of the common hCG metabolic products
associated with trophoblastic diseases, but the DPC test
yielded results that differed from the hCGb RIA data in 10
of 59 patients with trophoblast disease. In 7 of these 10
cases, the DPC result was close to the mean result for the
7 assays evaluated (within 25%; data not shown), but not
close to the hCG RIA data. Thus, the error may lie with
the RIA result rather than with the DPC values. The DPC
and other similarly designed tests might today be the tests
of choice for diagnosing and monitoring trophoblastic
diseases and for other applications requiring careful de-
tection of true-positive hCG and recognition of both intact
hCG and hCG metabolic products.
The research was supported by Grant HD35654 from the
National Institute of Child Health and Human Develop-
ment, NIH to Laurence Cole.
References
1. Elliott MM, Kardana A, Lustbader JW, Cole LA. Carbohydrate and
peptide structure of the a- and b-subunits of human chorionic
gonadotropin from normal and aberrant pregnancy and choriocar-
cinoma. Endocrine 1997;7:15–32.
2. Cole LA. Immunoassay of hCG, its free subunits and metabolites.
Clin Chem 1997;43:2233–43.
3. Cole LA, Kardana A. Discordant results in human chorionic gonad-
otropin assays. Clin Chem 1992;38:263–70.
4. Cole LA. hCG, its free subunits and metabolites in pregnancy and
trophoblastic Disease. J Reprod Med 1998;43:3–10.
5. Stenman U-H, Unkila-Kallilo L, Korhonen J, Alfthan H. Immunopro-
cedures for detecting human chorionic gonadotropin: clinical
aspects and doping control. Clin Chem 1997;43:1293–8.
314 Cole et al.: hCG in Trophoblastic Diseases
6. Mann K, Saller B, Hoermann R. Clinical use of hCG and hCG b
determinations. Scand J Clin Lab Invest 1993;S97–104.
7. Bagshawe K. Limitations of tests for human chorionic gonadotro-
pin. Lancet 2000;355:671.
8. Rinne K, Shahabi S, Cole LA. Following metastatic placental site
trophoblastic tumor with urine b-core fragment. Gynecol Oncol
1999;74:302–3.
9. Hussa RO, Rinke ML, Schweitzer PG. Discordant human chorionic
gonadotropin results: causes and solutions. Obstet Gynecol
1985;65:211–9.
10. Mitchell H. Analysis of hCG: clinical applications and assay
requirements Ann Clin Biochem 1999;36:259–60.
11. Norman RJ, Buck RH, Joubert SM. Comparison of human chorionic
gonadotrophin concentrations in the sera of patients with normal
and abnormal pregnancy measured by radioimmunoassay and
immunoradiometric assay. S Afr Med J 1989;75:318–9.
12. Matsuura Y, Kashimura M, Shinohara M, Baba S, Kondo M,
Kashimura Y. The follow-up of trophoblastic disease by using an
hCG C-terminal peptide enzyme immunoassay. Gan No Rinsho
1990;36:2559–62.
13. Wilson AP, Van Dalen A, Sibley PE, Kasper LA, Durham AP, el
Shami AS. Multicentre tumour marker reference range study.
Anticancer Res 1999;19:2749–52.
14. Ibuki Y, Yazaki K, Igarashi M. A highly sensitive and specific
sandwich enzyme immunoassay for detection of human chorionic
gonadotropin in trophoblastic disease. Asia Oceania J Obstet
Gynaecol 1990;16:49–56.
15. Wu AH, Wong SS, Waldron C, Chan DW. Automated quantification
of choriogonadotropin: analytical correlation between serum and
urine with creatinine correction. Clin Chem 1987;33:1424–6.
16. Rotmensch S, Cole LA. False diagnosis and needless therapy of
presumed malignant disease in women with false-positive human
chorionic gonadotropin concentrations. Lancet 2000;355:712–5.
17. Cole LA, Rinne KM, Shahabi S, Omrani A. False-positive hCG
assay results leading to unnecessary surgery and chemotherapy
and needless occurrences of diabetes and coma [Letter]. Clin
Chem 1999;45:313–4.
18. Berglund L, Holmberg NG. Heterophilic antibodies against rabbit
serum causing falsely elevated gonadotropin levels. Acta Obstet
Gynecol Scand 1989;68:377–8.
19. Cole LA. Phantom hCG and phantom choriocarcinoma. Gynecol
Oncol 1998;71:325–9.
20. Newlands E. Presentation and management of persistent gesta-
tional trophoblastic disease and gestational trophoblastic tumors
in the UK. In: Hancock BW, Newlands ES, Berkowitz RS, eds.
Gestational trophoblastic diseases. London: Chapman & Hall,
1997:143–56.
21. Birken S, Canfield RE. Structural and immunochemical properties
of human choriogonadotropin. In: McKerns KW, ed. Structure and
function of the gonadotropins. New York: Plenum Press, 1978:
47–80.
22. Storring PL, Gaines-Das RE, Bangham DR. International Reference
Preparation of Human Chorionic Gonadotrophin for Immunoassay:
potency estimates in various bioassay and protein binding assay
systems; and International Reference Preparations of the a and b
subunits of human chorionic gonadotrophin for immunoassay. J
Endocrinol 1980;84:295–310.
23. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A,
Canick JA, et al. Prenatal screening for Down’s syndrome with use
of maternal serum markers, N Engl J Med 1992;327:588–93.
24. Cole LA, Shahabi S, Oz UA, Bahado-Singh RO, Mahoney MJ. Hy-
perglycosylated hCG (invasive trophoblast antigen) immunoassay:
a new basis for gestational Down syndrome screening. Clin Chem
1999;45:2109–19.
25. Berkowitz RS, Goldstein DP. Presentation and management of
persistent gestational trophoblastic disease and gestational tro-
phoblastic tumors in the USA. In: Hancock BW, Newlands ES,
Berkowitz RS, eds. Gestational trophoblastic diseases. London:
Chapman & Hall, 1997:159–74.
26. Berkowitz RS, Goldstein DP. Presentation and management of
molar pregnancy. In: Hancock BW, Newlands ES, Berkowitz RS,
eds. Gestational trophoblastic diseases. London: Chapman &
Hall, 1997:127–42.
27. Dericks-Tan JS, Jost A, Schwedes U, Taubert HD. Pseudohypergo-
nadotropinemia and pseudohyperprolactinemia induced by het-
erophilic antibodies? Klin Wochenschr 1984;62:265–73.
Clinical Chemistry 47, No. 2, 2001 315
